Table 1. Baseline Clinical and Procedural Characteristics and Medications.
| SES stratum | BMS stratum | |
|---|---|---|
| (N = 5078) | (N = 5392) | |
| Clinical Characteristics | ||
| Age, years | 68.4±10.4 | 67.9±11.8 |
| Age > = 75 years | 1547 (31%) | 1717 (32%) |
| Male | 3624 (71%) | 3922 (73%) |
| BMI | 23.8±3.4 | 23.7±3.5 |
| BMI <25.0 | 3408 (67%) | 3745 (69%) |
| Hypertension | 4212 (83%) | 4364 (81%) |
| Diabetes mellitus | 2069 (41%) | 1787 (33%) |
| Diabetes with insulin therapy | 520 (10%) | 255 (4.7%) |
| Current smoking | 1372 (27%) | 1988 (37%) |
| Acute myocardial infarction | 820 (16%) | 2890 (54%) |
| Heart failure | 875 (17%) | 1182 (22%) |
| Shock at presentation | 114 (2.2%) | 499 (9.3%) |
| Multivessel disease | 2966 (58%) | 2420 (45%) |
| Mitral regurgitation grade 3/4 | 164 (3.2%) | 230 (4.3%) |
| LVEF, % | 59.9±12.9 | 57.8±13.1 |
| Previous myocardial infarction | 685 (14%) | 382 (7.1%) |
| Previous stroke | 579 (11%) | 506 (9.4%) |
| Peripheral vascular disease | 403 (7.9%) | 394 (7.3%) |
| eGFR <30 ml/min/1.73m2, not on dialysis | 198 (3.9%) | 234 (4.3%) |
| Dialysis | 228 (4.5%) | 116 (2.2%) |
| Atrial Fibrillation | 404 (8.0%) | 489 (9.1%) |
| Anemia (Hemoglobin <11 g/dl) | 582 (12%) | 614 (11%) |
| Thrombocytopenia (Platelet <100 109/L) | 72 (1.4%) | 79 (1.5%) |
| COPD | 172 (3.4%) | 211 (3.9%) |
| Liver cirrhosis | 116 (2.3%) | 154 (2.9%) |
| Malignancy | 441 (8.7%) | 539 (10%) |
| Procedural Characteristics | ||
| Number of target lesions | 1.47±0.74 | 1.30±0.62 |
| Target of proximal LAD | 3159 (62%) | 2804 (52%) |
| Target of unprotected LMCA | 172 (3.4%) | 154 (2.9%) |
| Target of CTO | 673 (13%) | 339 (6.3%) |
| Target of bifurcation, | 1981 (39%) | 1217 (23%) |
| Bifurcation with side-branch stenting, | 246 (4.8%) | 127 (2.4%) |
| Total number of stents | 1.90±1.22 | 1.46±0.82 |
| Total stent length, mm | 42.3±30.2 | 29.1±18.8 |
| Total stent length >28mm | 2674 (53%) | 1804 (34%) |
| Minimum stent size, mm | 2.83±0.37 | 3.09±0.49 |
| Minimum stent size <3.0mm | 2538 (50%) | 1576 (29%) |
| Baseline medication | ||
| Antiplatelet therapy | ||
| Thienopyridine | 5062 (99.7%) | 5288 (98%) |
| Ticlopidine | 4503 (89%) | 4887 (91%) |
| Clopidogrel | 551 (11%) | 380 (7.0%) |
| Aspirin | 5010 (99%) | 5318 (99%) |
| Cilostazole | 791 (16%) | 1204 (22%) |
| Other medications | ||
| Statins | 2737 (54%) | 2594 (48%) |
| Beta-blockers | 1418 (28%) | 1717 (32%) |
| ACE-I/ARB | 2797 (55%) | 3259 (60%) |
| Nitrates | 1882 (37%) | 1789 (33%) |
| Calcium channel blockers | 2369 (47%) | 1858 (35%) |
| Nicorandil | 1087 (21%) | 1350 (25%) |
| Warfarin | 413 (8.1%) | 404 (7.5%) |
| Proton pump inhibitors | 1183 (23%) | 1498 (28%) |
| H2-blockers | 1198 (24%) | 1515 (28%) |
ACE-I = angiotensin converting enzyme inhibitors, ARB = angiotensin II receptor blockers, BMI = body mass index, BMS = bare-metal stents, COPD = chronic obstructive pulmonary disease, CTO = chronic total occlusion, eGFR = estimated glomerular filtration rate, LAD = left anterior descending coronary artery, LMCA = left main coronary artery, LVEF = left ventricular ejection fraction, and SES = sirolimus-eluting stents.